ArticleAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology2026
Clinician and family perspectives on the use of single maintenance and reliever therapy for children.
Article in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundSingle maintenance and reliever therapy (SMART) is the guideline-recommended treatment for children with moderate to severe asthma, yet it is underutilized in pediatric practice.
objectiveTo understand barriers and facilitators to SMART adoption within pediatric practice.
methodsWe interviewed 52 participants (16 pediatricians, 22 parents, and 16 children). Interviews were conducted until theme saturation, recorded, transcribed, coded, and qualitatively analyzed using the Consolidated Framework for Implementation Research.
resultsWe identified barriers, facilitators, and potential solutions to SMART implementation. Participants described barriers at the following levels: (1) the clinic level, which included a lack of clinician training and clinical decision support for SMART; (2) the family level, which included discomfort transitioning away from traditional albuterol and concern about SMART's effectiveness as a rescue medication; and (3) the school and systems levels, which included poor communication and a lack of aligned care plans across community settings like schools, and challenges navigating insurance coverage. Facilitators to SMART implementation included acceptance of SMART as a simpler treatment that could improve asthma symptoms. Proposed solutions to barriers included the following: (1) clinic-level trainings and integrated clinical decision support; (2) family-level support for reluctant families; and (3) clear communication between clinics and schools, access to SMART-specific medication orders and action plans, and insurance support.
conclusionMost pediatricians and families reported that SMART is a favorable, simple, and acceptable treatment approach for children with asthma. However, pediatricians and families described significant barriers to using guideline-concordant SMART in routine practice. These results could inform targeted efforts to improve the adoption of SMART within pediatric asthma care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.